Sionna Therapeutics (SION) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Sionna Therapeutics (SION) over the past year, losing 3.1% versus a loss of 87.8%. Sionna Therapeutics is the larger company by market cap ($175.6 million vs $170.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SION | YARW |
|---|---|---|
| Share price | $3.89 | $18.31 |
| Market cap | $175.63M | $170.36M |
| 1-day change | -4.66% | -8.45% |
| YTD return | -90.54% | -36.86% |
| 1-year return | -87.82% | -3.12% |
| 5-year return | — | -98.22% |
| EPS (TTM) | $-2.16 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $570.00K |
| Revenue growth (YoY) | — | +13.77% |
| Net income (latest FY) | $-75.27M | $-26.48M |
| Operating margin | — | -5219.12% |
| Net margin | — | -4646.14% |
| 52-week high | $54.97 | $46.95 |
| 52-week low | $3.78 | $16.05 |
| Distance from 52-week high | -92.92% | -61.00% |
| Analyst consensus | hold | none |
| Avg. price target upside | +439.85% | +211.31% |
| Average volume | 2.22M | 92.05K |
| Shares outstanding | 45.15M | 9.30M |
| Employees | 59 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed SION by 84.7 percentage points over the past year.
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
SION vs YARW FAQ
Which is bigger, Sionna Therapeutics or Yarrow Bioscience?
Sionna Therapeutics (SION) is larger, with a market capitalization of $175.63M compared with $170.36M for Yarrow Bioscience (YARW).
Which stock has performed better over the past year, SION or YARW?
YARW returned -3.12% over the past 12 months, compared with -87.82% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Sionna Therapeutics and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.